A b s t r a c t
Transfusion of virtually all blood products is implicated as a cause of transfusion-related acute lung injury (TRALI). The National Heart, Lung, and Blood Institute Working Group and a Canadian consensus conference on TRALI defined TRALI as a new acute lung injury that occurs during or within 6 hours after a transfusion. 1 In addition to infusion of packed RBCs, platelets, and fresh frozen plasma, 2, 3 transfusion of allogeneic stem cells and intravenous administration of immunoglobulin [4] [5] [6] and granulocytes 7 have been implicated as causes of TRALI.
HLA antibodies, along with biologically active lipids or substances that accumulate in stored blood, are implicated in the pathogenesis of TRALI. Transfused leukoagglutinating antibodies bind to recipients' neutrophils localized to pulmonary endothelium, resulting in activation and release of oxidases and other damaging biologic response modifiers that cause capillary leak. In a minority of TRALI cases, no antibodies are identified and it is postulated that neutrophil priming factors in the transfused component can mediate TRALI in a patient with pulmonary endothelial activation, the socalled 2-hit mechanism. 8 In recent years, TRALI has become the leading cause of transfusion-related death reported to the US Food and Drug Administration. 7 In addition, researchers have found granulocytes and lymphocytotoxic antibodies in the serum samples of patients who received implicated blood and blood products containing plasma. Therefore, we implemented changes in the laboratory software (ePROGESA, Upon completion of this activity you will be able to:
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MAK-SYSTEM International Group, Paris, France) used for blood donors to quarantine all plasma products obtained from HLA-immunized blood donors.
As described herein, we reviewed HLA antibody testing using an enzyme-linked immunosorbent assay (ELISA) for all male blood donors at our institution during a 3.5-month period. The 6 purposes of this review were to: (1) confirm the results of the presence of HLA antibodies in our male blood donors using the GTI ELISA-based (DonorScreen) method (GTI Diagnostics, Waukesha, WI) with the fluorescent bead method for HLA antibody screening (Luminex, Austin, TX); (2) determine the number of false-positive results of the HLA-immunized male blood donors obtained using the ELISA-based DonorScreen method; (3) review the HLA-antibody specificities of HLA class I and class II of the male blood donors and correlate them with the donors' transfusion histories; (4) identify cognate antigens in recipients of packed RBCs and platelets obtained from male HLA-immunized donors; (5) review and investigate the reported transfusion reactions in the recipients; and (6) validate the performance of our MAK software program with the implemented changes resulting in quarantining the plasma obtained from HLA-immunized male donors. We also sought to determine the incidence of HLA sensitization in our male donor population and its impact on our institution's blood supply and the clinical significance of cognate HLA antigens and HLA antibodies in our recipients of packed RBCs and/or platelets from these donors.
Materials and Methods
A retrospective search of our whole blood donor records identified a total of 7,000 eligible whole blood donors, of whom 3,533 (50.5%) were female and 3,467 (49.5%) were male, who donated blood at our institution's blood donor center from September to December 2008. Of the male donors (age range, 17-78 years), 46 tested positive for HLA class I and/or II antibodies according to the DonorScreen method. We located 33 of the 46 samples of these male donors that were submitted for HLA antibody testing to the HLA laboratory at our institution. All eligible donors consented to testing according to the current regulatory standards and standard operating procedures for blood donation at the M. D. Anderson Blood Bank, Houston, TX. All samples used in this study were obtained from male donors who stated in their donor history questionnaires that they had not received any blood transfusions during the previous 12 months. Male HLA-immunized donors who tested positive for HLA antibodies were prospectively asked about their histories of blood transfusion.
The donor serum samples were initially screened for HLA class I and/or class II antibodies with a panel of fluorescent beads coated with HLA class I and class II antigen preparations (LABScreen Mixed, One Lambda, Canoga Park, CA) using the xMAP multiplex technology (Luminex). If this screen was negative for HLA class I and /or class II antibodies, no further testing was conducted. If this screen was positive, the donor serum samples were then screened for HLA class I and/ or class II antibody specificities using a panel of fluorescent beads coated with purified HLA class I and/or class II antigens (LABScreen PRA class I and II, LABScreen I Single Antigen [HLA class I and/or class II], One Lambda).
Patients were typed for alleles on the HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DRB3/4/5, and HLA-DQB1 loci using polymerase chain reaction (PCR) amplification and oligonucleotide hybridization via molecular methods (PCR sequence-specific primers and PCR sequence-specific oligonucleotide probes) or nucleotide sequencing (sequence-based testing) using commercially available kits (Protrans HLA, Protrans medizinische diagnostische Produkte, Hockenkeim, Germany; and Atria Genetics HLA typing test, Abbott Laboratories, Abbott Park, IL). The HLA specificities of the transfused blood products from HLA-immunized male donors and the recipient HLA phenotypes obtained by highresolution typing were reviewed.
Whole blood obtained from the male HLA-immunized donors was processed into the following components: packed RBCs, platelets, and plasma. The components were processed in accordance with current federal regulatory standards and in compliance with the standard operating procedures of the M. D. Anderson Blood Bank. The medical records of recipients of these products were reviewed, and their HLA antibody screens were noted ❚Table 1❚. HLA antibody specificities and HLA phenotypes were reviewed. All plasma products processed from the donors who tested positive for HLA class I and/or class II antibodies using the DonorScreen method were converted to recovered plasma. In addition, all packed RBCs and platelets were irradiated and transfused using a Sepacell RBC reduction filter (Fenwal, Lake Zurich, IL).
The electronic medical records of all patients at our institution who received blood or blood products from the male HLAimmunized donors were accessed to identify confirmed and potential clinical signs and symptoms of TRALI and possible TRALI according to the Canadian consensus conference definition of TRALI. The data required to review these transfusions are located in a single centralized clinical database at our institution. Transfused blood products are linked with donor records at the M. D. Anderson Blood Bank in a separate database.
The M. D. Anderson Blood Bank database was also searched for all reported transfusion reactions during the 3.5-month study period to identify confirmed and potential clinical signs and symptoms of TRALI and possible TRALI. In addition, HLA and platelet antibody testing results for all hospital patients from the same period were reviewed. and 6% (2/33) for the HLA class II antibody. We noted a false-positive result for the HLA class I antibody in 6% of the donors (2/33) and for the HLA class II antibody in 58% of the donors (19/33) using the DonorScreen method ❚Table 3❚ and ❚Table 4❚. Thus, we found that the DonorScreen method is less sensitive and specific than the fluorescent bead HLA antibody screen for HLA class II antibodies.
We also reviewed the final disposition of the blood products processed from each male HLA-immunized donor. We
In total, 30 units of packed RBCs and 21 units of random donor platelets were processed from the male HLA-immunized donors. The packed RBCs were transfused to 30 patients (20 female and 10 male). The platelets were pooled with other random donor units of platelets and transfused to 21 patients (14 female and 7 male) ( Table 1 ). The majority of the patients had hematopoietic and/or lymphoproliferative malignancies ❚Table 2❚. The transfused RBCs were all cross-matched and determined to be compatible with the recipients.
The samples obtained from the male HLA-immunized donors were not tested for antineutrophilic antibodies.
For each sample tested, the reported result (positive or negative) from the DonorScreen method was compared with the results from the LABScreen-Luminex HLA antibody screen. The true sensitivity and specificity were calculated based on a 2 × 2 contingency table from which the positive and negative predictive values were calculated. For comparison of the 2 methods, we used the McNemar test to obtain P values.
Results
We found that the DonorScreen method was significantly more specific for HLA class I antibodies than for HLA class II antibodies (P ≤ .0001; McNemar test). The agreement between the DonorScreen and Luminex HLA antibody screening results was 21% (7/33) for the HLA class I antibody met our goal of reserving 100% of the plasma products from the donors as recovered plasma and validated the performance of the implemented MAK software program in restricting the release of plasma from these HLA-immunized male donors for transfusion to our patients. We found no reported transfusion reactions in the recipients packed RBCs or platelets obtained from donors who tested positive for HLA class I and/or II antibodies according to the DonorScreen method ❚Table 5❚. 9 Two of the recipients of packed RBCs had HLA antibodies that corresponded to cognate antigens in the donors ❚Table 6❚. Also, 3 recipients of platelets had HLA antibodies that corresponded to cognate antigens in the donors ❚Table 7❚. The diagnoses in these cases included hematologic and nonhematologic conditions (Tables 6 and 7) .
Furthermore, 13 (39%) of the donors did not have a history of blood transfusion; thus, immunization against HLAs Anti-A32, A74, A66, A68, A33, A36, A66, A11, A34, A1, A24, A26, A29, A43, A23, A3  HLA-B  Anti-B38, B46, B13, B63, B76, B37, B65, B73, B53, B18, B82, B48, B78, B45, B51, B27, B39, B8, B75, B56,  B47, B62, B72, B60, B41, B50, B64, B54, B81, B55, B75, B61, B67, B42 , B35, B71, B7 HLA-C Anti-Cw18, Cw14, Cw8, Cw5, Cw6, Cw12, Cw4, Cw10, Cw9, Cw17, Cw7, Cw1 HLA-DR Anti-DR17, DR14, DR9, DR4, DR 53 HLA-DQ Anti-DQ7, DQ8, DQ9 HLA-DP Anti-DP1, DP5 4 * HLA-A Anti-A11 HLA-B Anti-B48, B60, B7, B81 HLA-DR Anti-DR1, DR103, DR17, DR4, DR7, DR9 5 * HLA-A Anti-A26, A29, A3, A30, A32, A33, A34, A36, A43, A68 HLA-B Anti-B37, B39, B41, B47, B50, B54, B57, B58, B61, B63, B64, B67, B73, B75 HLA-C Anti-Cw1, Cw10, Cw12, Cw14, Cw15, Cw47, Cw18, Cw2, Cw4, Cw5, Cw6, Cw7, Cw8, Cw9 6 * HLA-A AntiA26, A29, A3, A30, A34, A43, A68 HLA-B Anti-B13, B41, B45, B47, B60, B61, B82 HLA-C Anti-Cw1, Cw10, Cw12, Cw15, Cw17, Cw2, Cw4, Cw5, Cw6, Cw7, Cw8, Cw9 7 * HLA-A Anti-A2  HLA-B  Anti-B13, B27, B38, B42, B47, B48, B55, B56, B59, B60, B61, B67, B7, B81  8  HLA-B  Anti-B7, B8, B27, B38, B39, B42, B48, B55, B56, B59, B64, B65, B67, B71, B72, B73, B81, B82 by transfusion of blood and blood products was ruled out. One of the donors had a history of transfusion, and the HLA antibody screening was negative for HLA antibodies for this donor. Of the 8 donors (24%) positive for HLA antibodies according to the Luminex HLA antibody screen, 5 (15%) did not have a history of blood transfusion. We also made the interesting observation that 64% of the donors (21/33) positive for HLA antibodies according to the DonorScreen method had O+ blood. This observation deserves further study because the frequency of blood group O ranges from 27% to 48%, depending on the ethnicity of the population.
Discussion
According to our review, the GTI ELISA (DonorScreen) method is too sensitive and may result in high false-positive rates in the detection of HLA class II antibodies in blood donors. Although the DonorScreen in particular achieves its goal of reducing the risk of TRALI and promotes safe practice in blood transfusion, 10 it is not cost-effective and may result in unnecessary donor exclusion. A cost analysis was performed according to institutional guidelines to arrive at this conclusion.
As described previously, the presence of HLA antibodies in blood donors that correspond to cognate antigens in recipients is not the only factor that enhances acute lung injury in TRALI. Additional patient-related factors include the presence of antineutrophilic antibodies, biologically active substances such as lipids and cytokines, and CD40L-primed neutrophils that cause a reaction when transfused to susceptible patients. [11] [12] [13] Authors have reported the presence of "natural" HLA antibodies in healthy nonalloimmunized males. 14 In this retrospective review, we observed that HLA antibodies frequently, as well as infrequently, had HLA specificities to HLA class I and/ or class II antigens that may have been produced in response to cross-reactive epitopes found in microorganisms, ingested proteins, and allergens in our male blood donors. HLA antibodies and neutrophil-specific antibodies have been found in male donors and have been implicated in cases of TRALI. 15 We implemented universal testing of all blood donors for HLA antibodies in our institution's blood donor center to comply with the TRALI risk-reduction strategy. 16 This testing has resulted in a reduction in the number of donated blood products because of the low positive antibody positive cutoff values currently used for HLA class II antibodies with the DonorScreen method. We also purchase blood and blood components from other donor centers that do not perform universal testing for HLA antibodies. Transfusion of these components has not produced any reported adverse reactions in our patients.
The results of this retrospective review prompted us to review universal testing of all of our blood donors for HLA antibodies. We thought that the GTI ELISA-based testing with DonorScreen led to exclusion of more donors than necessary. We reported the DonorScreen results as positive for HLA class I and/or class II antibodies when the optical density values were greater than or equal to twice the value obtained for the mean of the negative control for each HLA class. The negative and positive HLA class I and class II control samples were purchased from the manufacturer. We considered testing female blood donors with a history of 3 or more pregnancies and male donors with a history of transfusion for HLA antibodies with the hope of eliminating donors having HLA antibodies over the long-term at potentially high levels. 17, 18 Men who have not received transfusions reportedly have HLA antibody reactivity rates comparable with those in nulliparous women. 19 A study of 44 parous women with known histories of the presence of HLA antibodies according to lymphocytotoxicity assays revealed persistently positive HLA antibody testing results during 13 years, with most of the subjects having strongly positive screening results and antibody specificity throughout this period. Prior studies revealed that in approximately half of all women with HLA antibodies in the postpartum period, these antibodies disappear during the ensuing 6 months to 5 years. [20] [21] [22] In 1 study, the HLA antibody prevalence seemed to decline more slowly after its initial decrease during the first 5 years. 22 Investigators have explored the use of a new multiplex bead-based Luminex technology for HLA antibody testing in blood donors and found that it had limitations associated with sample type and processing; however, that study confirmed that high levels of HLA antibodies are detectable in blood donors over long periods. 23 Our study has several limitations. It was a retrospective review and consisted of a small number of HLA-immunized male donors. Also, end points were measured by reported transfusion reactions to the blood bank and not by study protocol. The HLA antibodies of the index donors could have changed, and recipient factors, for example, priming activity in patient plasma before transfusion, were not evaluated.
We, however, concluded that allowing females with a history of 3 of more pregnancies to donate whole blood and processing plasma as recovered plasma is a more effective donor management strategy and a more effective TRALI risk-reduction strategy than performing HLA antibody testing of all blood donors. We believe that this has resulted in a more effective strategy of screening a subpopulation of possibly "HLA-immunized" potential donors before they actually donate blood, reducing the risk of confusing and alienating donors about the implications of testing positive for HLA antibodies 24 and lessening the impact of donor loss and donor management on our blood supply over the long-term.
